Therapeutic methods employing mutant human interleukin-3 (IL-3)

Details Therapeutic methods employing mutant human interleukin-3 (IL-3) Therapeutic methods employing mutant human interleukin-3 (IL-3)

1995-06-06

2000-01-25

Fitzgerald, David L.

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

930141, A61K 3820, C12N 1524, C07K 1454

Patent

active

060175230

ABSTRACT:
The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain one to three amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (corresponding to residues 119 to 133) have been deleted from the C-terminus, and which also contain one to three amino acid substitutions in the polypeptide. These hIL-3 mutant polypeptides may have biological activities similar to or better than hIL-3 and, in some cases, may also have an improved side effect profile.

REFERENCES:
patent: 4877729 (1989-10-01), Clark et al.
patent: 4959455 (1990-09-01), Clark et al.
patent: 5032395 (1991-07-01), Clark et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5591427 (1997-01-01), Vadas
patent: 5677149 (1997-10-01), Bauer et al.
Yang et al, in Cell 47:3 (1986).
Dorsers et al, Gene 55:115 (1987).
Phillips et al, Gene, 84, 501 (1989).
Clark-Lewis et al, Science 231:134 (1986).
Clark-Lewis et al, Proc.Nat.Acad.Sci.USA 85:7897 (1988).
Lokker et al, J. Biol. Chem., 266 (16):10624 (1991).
Clark-Lewis et al, Immune Regulation by Characterized Polypeptides, Alan R. Liss, Inc. (1987) pp. 323-334.
Ihle et al, J. Immunol. 126:2184 (1981).
Fung et al, Nature, 307, 233 (1984).
Yokota et al, Proc.Nat.Acad.Sci. USA 81:1070 (1984).
Dorssers et al, J.Biol.Chem 266 (31):21310 (1991).
Koshansky et al, J.Clin.Invest, 90:1879 (1992).
Lopez et al, Proc.Natl.Acad.Sci. USA 89:11842-11846 (1992).
Lokker et al, The EMBO Jour. 10:2125-2131 (1991).

Affiliated with

Also associated with

Rating

Therapeutic methods employing mutant human interleukin-3 (IL-3) does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic methods employing mutant human interleukin-3 (IL-3) , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic methods employing mutant human interleukin-3 (IL-3) will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2313813